Company news

Bayer AG news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Bayer Shares New Post Hoc Analysis Of Self-Reported Sleep-Related Outcomes with Lynkuet® (elinzanetant) in Women with Moderate to Severe Vasomotor Symptoms at the Menopause Society Annual Meeting

October 26, 2026

Asundexian first Factor XIa inhibitor approved in China for stroke risk reduction after priority review

October 26, 2026

ESMO 2026: NUBEQA® (darolutamide) Plus ADT and Radiation Therapy Reduces Risk of Metastasis or Death by 58% in Prostate Cancer Patients at High Risk of Recurrence

October 24, 2026

Bayer to Present New Cardiac Amyloidosis and Heart Failure Data at the Heart Failure Society of America (HFSA) Annual Scientific Meeting

October 8, 2026

Actress and Menopause Advocate Melissa Joan Hart Partners with Bayer to Raise Awareness about Lynkuet® (elinzanetant), a Prescription Treatment for Moderate to Severe Hot Flashes due to Menopause

October 8, 2026

U.S. FDA Accepts Bayer’s Supplemental New Drug Application for KERENDIA® (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without Diabetes

October 8, 2026

Bayer to Invest $2.2 Billion in a New Manufacturing Site in Ohio

October 2, 2026

Bayer to Invest 2.2 Billion U.S. Dollars in a New Manufacturing Site in the United States

October 2, 2026

Bayer appoints Dr. Christoph Koenen, MD, as Chief Medical Officer

October 1, 2026

BlueRock Therapeutics’ investigational cell therapy lemiretprocel (OpCT-001) for primary photoreceptor diseases granted orphan drug designations by FDA and EMA

September 30, 2026

MiraSOFT™ Launch at CVS Pharmacy, Expanding the MIRA Portfolio with a Stool Softener Option

September 29, 2026

U.S. FDA Accepts sNDA and Grants Priority Review to Bayer’s Lynkuet® (elinzanetant) for a New Indication for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Endocrine Therapy Related to Breast Cancer

September 28, 2026

Bayer’s KERENDIA® (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 Diabetes

September 17, 2026

Apollo Funds Complete €3 Billion Capital Solution for Bayer

September 16, 2026

Bayer Launches Nationwide Science Delivers Tour to Take Science on the Road

September 10, 2026

U.S. FDA Grants Accelerated Approval to Bayer’s HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung Cancer

September 9, 2026

Bayer and Neste Close Commercial Agreement to Jointly Scale newgold® Winter Canola for Biofuels Production

September 9, 2026

BAYER initiates Phase II study of investigational GIRK4 inhibitor in patients with atrial fibrillation

September 9, 2026

Bayer initiates Phase II study of investigational GIRK4 inhibitor in patients with atrial fibrillation

September 9, 2026

First licensed treatment now available for condition behind the UK’s leading cause of horse euthanasia

September 8, 2026

Bayer Advances Combined Seed and Crop Protection Pipeline and Enters Phase of Blockbuster Launches

September 3, 2026

Finerenone slowed kidney function decline and reduced kidney-cardiovascular risk versus placebo in patients with hypertensive nephropathy

August 31, 2026

Bayer Announces Phase III REVEAL Study with Investigational PET Radiotracer Iodine 124 Evuzamitide Presented as Late-Breaker at ESC 2026

August 30, 2026

Bayer: AskBio Presents Baseline Characteristics from Phase 2 Heart Failure Gene Therapy Trial of Umiposgene Parvec (AB-1002) at European Society of Cardiology Congress

August 29, 2026

Bayer sevabertinib approved in Japan for patients with HER2-mutant non-small cell lung cancer

August 24, 2026

Bayer to Present New Phase III Data from Its Cardiovascular, Kidney, and Stroke Clinical Trial Programs at ESC 2026

August 20, 2026

Aflibercept 8 mg application for macular edema following retinal vein occlusion accepted for review in China

August 13, 2026

Bayer operationally on track, decisive progress on strategic priorities

August 4, 2026

Bayer submits application for next indication of Kerendia in China

July 30, 2026

New Economist Enterprise Research Highlights Why Integrating Self-Care Into Health Systems Matters

July 23, 2026

Bayer and Henry Ford Health Announce Strategic Research Partnership to Expand Patient Access to Clinical Trials

July 17, 2026

European Commission approves JASCAYD®, bringing well-tolerated, novel oral treatment for IPF and PPF to the EU

July 17, 2026

Bayer signs licensing agreement with RAGT and begins broad hybrid wheat commercialization by early 2030s

July 15, 2026

Bayer: Sabanto and Leaps by Bayer Announce Oversubscribed Series B Financing to Scale Autonomous Technology for Row Crop Farming

July 14, 2026

Bayer Aktiengesellschaft: Bayer secures 3.0 billion euros to improve capital structure

July 10, 2026

The University of Colorado Anschutz, along with UCHealth and Children’s Hospital Colorado, Form Strategic Alliance with Bayer to Advance Drug Development and Clinical Trials

July 7, 2026

Bayer Group to Consolidate U.S. Glyphosate Business Into Distinct Entity Operating as Ruveon

July 1, 2026

Bayer Welcomes Kacy Perry as New Country Division Head for Crop Science Canada

June 18, 2026

Federal judge remands Monsanto class settlement case back to Missouri State Court

June 17, 2026

Natur Tec India and Bayer to Develop Compostable Seedling Cups

June 16, 2026

Bayer low-dose MRI contrast agent approved in U.S.

June 15, 2026

Bayer’s AMBELVIST® (gadoquatrane) Receives FDA Approval for Contrast-Enhanced MRI to Detect and Visualize Lesions with Abnormal Vascularity in the Central Nervous System and Non-CNS Body Regions

June 15, 2026

Bayer: European Medicines Agency confirms asundexian marketing authorization application for assessment in secondary prevention of ischemic stroke

June 10, 2026

Bayer Announces Advancement in Cardiovascular Health Assessment with Saudi Heart Association's recent publication on Early Detection of Subclinical Atherosclerosis in Clinical Practice

June 9, 2026

Bayer Announces Global Consumer Health Leadership Changes to Accelerate Growth

June 8, 2026

Bayer finerenone significantly reduced kidney function decline and a composite of cardiovascular-kidney outcomes versus placebo in patients with non-diabetic chronic kidney disease

June 5, 2026

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

June 2, 2026

ASCO 2026: Bayer Shares New Findings for NUBEQA® (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial

May 30, 2026

Kerendia™ approved in China for new indication in adult patients with heart failure with LVEF ≥40%

May 22, 2026

Boehringer Ingelheim’s oncology portfolio shows strong promise across multiple cancers at ASCO 2026

May 21, 2026

Older news releases →

Calls

The 5 newest of 10 calls. Every call is listed under its year.

Decks

The 5 newest of 137 decks. Every deck is listed under its year.